SLC16A10: A Drug Target / Disease Biomarker (G117247)

Target Name: SLC16A10

NCBI ID: G117247

SLC16A10

SLC16A10: A Drug Target / Disease Biomarker

SLC16A10 is a gene that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its encoded protein, SLC16A10, is a zinc transporter that is expressed in many different tissues and cells in the body. It is known for its role in the regulation of zinc homeostasis, which is essential for the proper functioning of many cellular processes.

SLC16A10 has been shown to be involved in a number of physiological processes that are important for human health, including the development and progression of cancer, the development of neurodegenerative diseases, and the regulation of inflammation. It is also thought to be involved in the regulation of pain perception and the modulation of pain relief.

SLC16A10 has been identified as a potential drug target by researchers because it is expressed in a wide variety of tissues and cells, including those that are affected by many different diseases. It is also known to be involved in the regulation of a number of important cellular processes, which makes it an attractive target for drug development. Additionally, because SLC16A10 is expressed in many different tissues and cells, it is likely to be involved in a wide range of physiological processes that are important for human health.

One of the potential benefits of targeting SLC16A10 as a drug target is that it is thought to be involved in the regulation of a wide range of cellular processes that are important for human health. This makes it an attractive target for drug development because it is likely to have a large number of potential drug targets that can be targeted. Additionally, because SLC16A10 is expressed in many different tissues and cells, it is likely to be involved in a wide range of physiological processes that are important for human health. This could make it an attractive target for drug development because it is likely to have a large number of potential drug targets that can be targeted.

Another potential benefit of targeting SLC16A10 as a drug target is that it is thought to be involved in the regulation of a wide range of cellular processes that are important for human health. This makes it an attractive target for drug development because it is likely to have a large number of potential drug targets that can be targeted. Additionally, because SLC16A10 is expressed in many different tissues and cells, it is likely to be involved in a wide range of physiological processes that are important for human health. This could make it an attractive target for drug development because it is likely to have a large number of potential drug targets that can be targeted.

Targeting SLC16A10 as a drug target is also thought to have the potential to address a number of specific diseases. For example, SLC16A10 has been shown to be involved in the regulation of zinc homeostasis, which is essential for the proper functioning of many cellular processes. This makes it an attractive target for drug development because it is thought to be involved in the regulation of a wide range of cellular processes that are important for human health. Additionally, because SLC16A10 is expressed in many different tissues and cells, it is likely to be involved in a wide range of physiological processes that are important for human health. This could make it an attractive target for drug development because it is thought to be involved in the regulation of a wide range of cellular processes that are important for human health.

In addition to its potential as a drug target, SLC16A10 is also thought to be involved in the regulation of a number of other cellular processes that are important for human health. For example, SLC16A10 has been shown to be involved in the regulation of cell adhesion, which is important for the development and maintenance of tissues and organs. This makes it an attractive target for drug development because it is

Protein Name: Solute Carrier Family 16 Member 10

Functions: Sodium- and proton-independent thyroid hormones and aromatic acids transporter (PubMed:11827462, PubMed:18337592, PubMed:28754537). Mediates both uptake and efflux of 3,5,3'-triiodothyronine (T3) and 3,5,3',5'-tetraiodothyronine (T4) with high affinity, suggesting a role in the homeostasis of thyroid hormone levels (PubMed:18337592). Responsible for low affinity bidirectional transport of the aromatic amino acids, such as phenylalanine, tyrosine, tryptophan and L-3,4-dihydroxyphenylalanine (L-dopa) (PubMed:11827462, PubMed:28754537). Plays an important role in homeostasis of aromatic amino acids (By similarity)

The "SLC16A10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC16A10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets